The DOI matches its Crossref record; 132 of the 132 references it cites were found in a registry or an index.
Dysfunctional HDL and atherosclerotic cardiovascular disease
Open accessAbstract
High-density lipoproteins (HDLs) protect against atherosclerosis by removing excess cholesterol from macrophages through the ATP-binding cassette transporter A1 (ABCA1) and ATP-binding cassette transporter G1 (ABCG1) pathways involved in reverse cholesterol transport. Factors that impair the availability of functional apolipoproteins or the activities of ABCA1 and ABCG1 could, therefore, strongly influence atherogenesis. HDL also inhibits lipid oxidation, restores endothelial function, exerts anti-inflammatory and antiapoptotic actions, and exerts anti-inflammatory actions in animal models. Such properties could contribute considerably to the capacity of HDL to inhibit atherosclerosis. Systemic and vascular inflammation has been proposed to convert HDL to a dysfunctional form that has impaired antiatherogenic effects. A loss of anti-inflammatory and antioxidative proteins, perhaps in combination with a gain of proinflammatory proteins, might be another important component in rendering HDL dysfunctional. The proinflammatory enzyme myeloperoxidase induces both oxidative modification and nitrosylation of specific residues on plasma and arterial apolipoprotein A-I to render HDL dysfunctional, which results in impaired ABCA1 macrophage transport, the activation of inflammatory pathways, and an increased risk of coronary artery disease. Understanding the features of dysfunctional HDL or apolipoprotein A-I in clinical practice might lead to new diagnostic and therapeutic approaches to atherosclerosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Some studies have indicated a complete loss of function and dysfunction gain concerning anti-inflammatory, vasodilatory, and antiapoptotic activities.”
From Residual Cardiovascular Risk: Role of Remnants Cholesterol, Monocyte/HDL Ratio and Lipoprotein Ratios on Personalized Cardiovascular Prevention (2024) · cites this paper as [9]
The cited source says what the claim attributes to it.
In the citing paper
“However, there are instances where HDL’s ability to deliver cholesterol esters via SCARB1 may be reduced, indicating only a partial loss of function.”
From Residual Cardiovascular Risk: Role of Remnants Cholesterol, Monocyte/HDL Ratio and Lipoprotein Ratios on Personalized Cardiovascular Prevention (2024) · cites this paper as [9]
The cited source says what the claim attributes to it.
In the citing paper
“It was noted that HDL could lose its anti-inflammatory properties and even develop proinflammatory characteristics.”
From Residual Cardiovascular Risk: Role of Remnants Cholesterol, Monocyte/HDL Ratio and Lipoprotein Ratios on Personalized Cardiovascular Prevention (2024) · cites this paper as [9]
The cited source says what the claim attributes to it.
In the citing paper
“However, when it comes to antioxidative activity and cholesterol efflux capacity, the deficiency observed in HDL’s normal function falls short of complete dysfunction [9].”
From Residual Cardiovascular Risk: Role of Remnants Cholesterol, Monocyte/HDL Ratio and Lipoprotein Ratios on Personalized Cardiovascular Prevention (2024) · cites this paper as [9]
The cited source says what the claim attributes to it.
In the citing paper
“Subsequent research has shown that the extent of HDL’s normal function loss and dysfunction gain can vary depending on its different biological activities.”
From Residual Cardiovascular Risk: Role of Remnants Cholesterol, Monocyte/HDL Ratio and Lipoprotein Ratios on Personalized Cardiovascular Prevention (2024) · cites this paper as [9]
The cited source says what the claim attributes to it.
In the citing paper
“Dysfunctional HDL (dys-HDL) are HDL cholesterol particles with high pro-atherogenic characteristics, characterized by the loss of typical antioxidant properties, becoming carriers of oxidized lipids themselves.”
From Residual Cardiovascular Risk: Role of Remnants Cholesterol, Monocyte/HDL Ratio and Lipoprotein Ratios on Personalized Cardiovascular Prevention (2024) · cites this paper as [9]
In the citing paper
“Moreover, modulations in HDL particle composition can transform it to dysfunctional and, through this modulation, increase the risk of CVD40.”
From Prolonged sleep restriction induces changes in pathways involved in cholesterol metabolism and inflammatory responses (2016) · cites this paper as [40]
In the citing paper
“Decrease in HDL has been regarded as one important risk factor for cardiovascular diseases40.”
From Prolonged sleep restriction induces changes in pathways involved in cholesterol metabolism and inflammatory responses (2016) · cites this paper as [40]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biological, clinical and population relevance of 95 loci for blood lipids
Teslovich, T. M., Musunuru, K., Smith, A. V., Edmondson, A. C., Stylianou, I. M., Koseki, M., Pirruccello, J. P., Ripatti, S., Chasman, D. I., Willer, C. J., et al. (2010) · Nature · doi:10.1038/nature09270 · Cited by 3,487
Self-citationEffects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Self-citationWiller (2013) · doi:10.1038/ng.2797 · Cited by 2,983
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Effects of dalcetrapib in patients with a recent acute coronary syndrome
Schwartz, G. G., Olsson, A. G., Abt, M., Ballantyne, C. M., Barter, P. J., Brumm, J., Chaitman, B. R., Holme, I. M., Kallend, D., Leiter, L. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206797 · Cited by 2,022
Self-citationCholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis
Khera, A. V., Cuchel, M., de la Llera-Moya, M., Rodrigues, A., Burke, M. F., Jafri, K., French, B. C., Phillips, J. A., Mucksavage, M. L., Wilensky, R. L., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1001689 · Cited by 1,943
Effects of extended-release niacin with laropiprant in high-risk patients
The HPS2-THRIVE Collaborative Group (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300955 · Cited by 1,668
Large-scale association analysis identifies new risk loci for coronary artery disease
The CARDIoGRAMplusC4D Consortium, Deloukas, P., DIAGRAM Consortium, CARDIOGENICS Consortium, MuTHER Consortium, Wellcome Trust Case Control Consortium, Kanoni, S., Willenborg, C., Farrall, M., Assimes, T. L., et al. (2013) · Nature Genetics · doi:10.1038/ng.2480 · Cited by 1,614
HDL cholesterol efflux capacity and incident cardiovascular events
Rohatgi, A., Khera, A., Berry, J. D., Givens, E. G., Ayers, C. R., Wedin, K. E., Neeland, I. J., Yuhanna, I. S., Rader, D. R., de Lemos, J. A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409065 · Cited by 1,390
Daugherty, A., Dunn, J. L., Rateri, D. L., & Heinecke, J. W. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117342 · Cited by 1,269
Self-citation
Cited by
Sorted by citations
Ginsberg, H. N., Packard, C. J., Chapman, M. J., Borén, J., Aguilar-Salinas, C. A., Averna, M., Ference, B. A., Gaudet, D., Hegele, R. A., Kersten, S., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab551 · Cited by 979
Self-citationEvacetrapib and cardiovascular outcomes in high-risk vascular disease
Lincoff, A. M., Nicholls, S. J., Riesmeyer, J. S., Barter, P. J., Brewer, H. B., Fox, K. A. A., Gibson, C. M., Granger, C., Menon, V., Montalescot, G., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609581 · Cited by 801
Self-citationMendelian randomization in cardiometabolic disease: challenges in evaluating causality
Holmes, M. V., Ala-Korpela, M., & Smith, G. D. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.78 · Cited by 679
Hypertriglyceridaemia and risk of coronary artery disease
Reiner, Ž. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.31 · Cited by 390
Enkavi, G., Javanainen, M., Kulig, W., Róg, T., & Vattulainen, I. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00538 · Cited by 293
A new perspective on lipid research in age-related macular degeneration
van Leeuwen, E. M., Emri, E., Merle, B. M. J., Colijn, J. M., Kersten, E., Cougnard-Gregoire, A., Dammeier, S., Meester-Smoor, M., Pool, F. M., de Jong, E. K., et al. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2018.04.006 · Cited by 247
Cardiovascular disease in diabetes, beyond glucose
Eckel, R. H., Bornfeldt, K., & Goldberg, I. J. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.07.001 · Cited by 235
Xiao, C., Dash, S., Morgantini, C., Hegele, R. A., & Lewis, G. F. (2016) · Diabetes · doi:10.2337/db16-0046 · Cited by 212
Antioxidant properties of anthocyanins and their mechanism of action in atherosclerosis
Garcia, C., & Blesso, C. N. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.05.040 · Cited by 218
Macrophagic CD146 promotes foam cell formation and retention during atherosclerosis
Luo, Y., Duan, H., Qian, Y., Feng, L., Wu, Z., Wang, F., Feng, J., Yang, D., Qin, Z., & Yan, X. (2017) · Cell Research · doi:10.1038/cr.2017.8 · Cited by 191
Gaforio, J. J., Visioli, F., Alarcón-de-la-Lastra, C., Castañer, O., Delgado-Rodríguez, M., Fitó, M., Hernández, A. F., Huertas, J. R., Martínez-González, M. A., Menendez, J. A., et al. (2019) · Nutrients · doi:10.3390/nu11092039 · Cited by 187
Marques, L. R., Diniz, T. A., Antunes, B. M., Rossi, F. E., Caperuto, É. C., Lira, F. S., & Gonçalves, D. C. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.00526 · Cited by 180
Awasthi, D., Nagarkoti, S., Kumar, A., Dubey, M., Singh, A. K., Pathak, P., Chandra, T., Barthwal, M. K., & Dikshit, M. (2016) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.01.004 · Cited by 181
High-Density Lipoprotein Anti-Inflammatory Capacity and Incident Cardiovascular Events
Jia, C., Anderson, J. L. C., Gruppen, E. G., Yu, L., Bakker, S. J. L., Dullaart, R. P. F., & Tietge, U. J. F. (2021) · Circulation · doi:10.1161/circulationaha.120.050808 · Cited by 179
Microdomains, Inflammation, and Atherosclerosis
Sorci-Thomas, M. G., & Thomas, M. J. (2016) · Circulation Research · doi:10.1161/circresaha.115.306246 · Cited by 165
The Aging Risk and Atherosclerosis: A Fresh Look at Arterial Homeostasis
Head, T., Daunert, S., & Goldschmidt‐Clermont, P. J. (2017) · Frontiers in Genetics · doi:10.3389/fgene.2017.00216 · Cited by 172
Luo, F., Das, A., Chen, J., Wu, P., Li, X., & Fang, Z. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0860-y · Cited by 165
Vascular endothelium dysfunction: a conservative target in metabolic disorders
Jamwal, S., & Sharma, S. (2018) · Inflammation Research · doi:10.1007/s00011-018-1129-8 · Cited by 161
New insight into dyslipidemia‐induced cellular senescence in atherosclerosis
Xiang, Q., Tian, F., Xu, J. R., Du, X., Zhang, S., & Liu, L. (2022) · Biological reviews/Biological reviews of the Cambridge Philosophical Society · doi:10.1111/brv.12866 · Cited by 169
HDL and atherosclerotic cardiovascular disease: genetic insights into complex biology
Rosenson, R. S., Brewer, H. B., Barter, P. J., Björkegren, J., Chapman, M. J., Gaudet, D., Kim, D. S., Niesor, E. J., Rye, K., Sacks, F. M., et al. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.115 · Cited by 149
Self-citationThe physiology of foamy phagocytes in multiple sclerosis
Grajchen, E., Hendriks, J. J. A., & Bogie, J. F. J. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0628-8 · Cited by 160
Fernández‐Sanlés, A., Sayols-Baixeras, S., Subirana, I., Degano, I. R., & Elosúa, R. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.05.022 · Cited by 140
Nazir, S., Jankowski, V., Bender, G., Zewinger, S., Rye, K.-A., & van der Vorst, E. P. C. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.10.006 · Cited by 140
Song, Y., Zhao, Y., Shu, Y., Zhang, L., Cheng, W., Wang, L., Shu, M., Xue, B., Wang, R., Feng, Z., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1100453 · Cited by 141
Impact of intermittent fasting on the lipid profile: Assessment associated with diet and weight loss
Santos, H. O., & Macedo, R. C. O. (2018) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2018.01.002 · Cited by 149
High Density Lipoproteins: Metabolism, Function, and Therapeutic Potential
Jomard, A., & Osto, E. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00039 · Cited by 154
Lipoprotein carriers of microRNAs
Michell, D. L., & Vickers, K. C. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2016.01.011 · Cited by 135
The Associations of Serum Lipids with Vitamin D Status
Wang, Y., Si, S., Liu, J., Wang, Z., Jia, H., Feng, K., Sun, L., & Song, S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0165157 · Cited by 142
Detection and treatment of atherosclerosis using nanoparticles
Zhang, J., Zu, Y., Dhanasekara, C. S., Li, J., Wu, D., Fan, Z., & Wang, S. F. (2016) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1412 · Cited by 132
Aho, V., Ollila, H. M., Kronholm, E., Bondia-Pons, I., Soininen, P., Kangas, A. J., Hilvo, M., Seppälä, I., Kettunen, J., Oikonen, M., et al. (2016) · Scientific Reports · doi:10.1038/srep24828 · Cited by 126
β-glucans and cholesterol (Review)
Šíma, P., Vannucci, L. E., & Větvička, V. (2018) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2018.3411 · Cited by 141
Li, J., Zhou, C., Xu, H., Brook, R. D., Liu, S., Yi, T., Wang, Y., Feng, B., Zhao, M., Wang, X., et al. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.311749 · Cited by 118
HDL in Immune-Inflammatory Responses: Implications beyond Cardiovascular Diseases
Bonacina, F., Pirillo, A., Catapano, A. L., & Norata, G. D. (2021) · Cells · doi:10.3390/cells10051061 · Cited by 119
An engineered S1P chaperone attenuates hypertension and ischemic injury
Swendeman, S. L., Xiong, Y., Cantalupo, A., Yuan, H., Burg, N. D., Hisano, Y., Cartier, A., Liu, C. H., Engelbrecht, E., Blaho, V. A., et al. (2017) · Science Signaling · doi:10.1126/scisignal.aal2722 · Cited by 111
Lipids and lipoproteins in cardiovascular diseases: a classification
Bhargava, S., de la Puente-Secades, S., Schurgers, L. J., & Jankowski, J. (2022) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2022.02.001 · Cited by 110
Gordon, E. M., Figueroa, D. M., Barochia, A. V., Yao, X., & Levine, S. J. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00323 · Cited by 112
Cardiopulmonary effects induced by occupational exposure to titanium dioxide nanoparticles
Zhao, L., Zhu, Y., Chen, Z., Xu, H., Zhou, J., Tang, S., Xu, Z., Kong, F., Li, X., Zhang, Y., et al. (2018) · Nanotoxicology · doi:10.1080/17435390.2018.1425502 · Cited by 114
Ebtehaj, S., Gruppen, E. G., Bakker, S. J. L., Dullaart, R. P. F., & Tietge, U. J. F. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.119.312645 · Cited by 105
Lu, L., Qi, S., Chen, Y., Luo, H., Huang, S., Yu, X. M., Luo, Q., & Zhang, Z. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.119987 · Cited by 106
Froyen, E., & Burns‐Whitmore, B. (2020) · Nutrients · doi:10.3390/nu12082329 · Cited by 108
High-Density Lipoproteins and Serum Amyloid A (SAA)
Webb, N. R. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00901-4 · Cited by 103
Self-citationApoA1 and ApoA1-specific self-antibodies in cardiovascular disease
Chistiakov, D. A., Orekhov, A. N., & Bobryshev, Y. V. (2016) · Laboratory Investigation · doi:10.1038/labinvest.2016.56 · Cited by 101
Kanter, J. E., & Bornfeldt, K. (2016) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.116.307302 · Cited by 103
The Importance of Lipoprotein Lipase Regulation in Atherosclerosis
Kumari, A., Kristensen, K. K., Ploug, M., & Winther, A.-M. L. (2021) · Biomedicines · doi:10.3390/biomedicines9070782 · Cited by 100
Recent Advances in the Development of Theranostic Nanoparticles for Cardiovascular Diseases
Wu, Y., Vazquez‐Prada, K. X., Liu, Y., Whittaker, A. K., Zhang, R., & Ta, H. T. (2021) · Nanotheranostics · doi:10.7150/ntno.62730 · Cited by 92
Is a High HDL-Cholesterol Level Always Beneficial?
Franczyk, B., Rysz, J., Ławiński, J., Rysz-Górzyńska, M., & Gluba-Brzózka, A. (2021) · Biomedicines · doi:10.3390/biomedicines9091083 · Cited by 94
Ito, F., & Ito, T. (2020) · Antioxidants · doi:10.3390/antiox9050362 · Cited by 87
The Impact of Cytokines in Coronary Atherosclerotic Plaque: Current Therapeutic Approaches
Tsioufis, P., Theofilis, P., Tsioufis, K. P., & Tousoulis, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415937 · Cited by 93
Singh, K., Chandra, A., Sperry, T., Joshi, P. H., Khera, A., Virani, S. S., Ballantyne, C. M., Otvos, J. D., Dullaart, R. P. F., Gruppen, E. G., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.045713 · Cited by 83
Liu, C., Zhang, Y., Ding, D., Li, X., Yang, Y., Li, Q., Zheng, Y., Wang, D., & Ling, W. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.10.111 · Cited by 85
Pircher, A., Treps, L., Bodrug, N., & Carmeliet, P. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.011 · Cited by 84
Barker, G., Leeuwenburgh, C., Brusko, T. M., Moldawer, L. L., Reddy, S. T., & Guirgis, F. W. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10081693 · Cited by 83
Potential Immunological Links Between Psoriasis and Cardiovascular Disease
Sajja, A. P., Joshi, A. A., Teague, H., Dey, A. K., & Mehta, N. N. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01234 · Cited by 80
Mészáros, M., & Bikov, A. (2022) · Biomedicines · doi:10.3390/biomedicines10112754 · Cited by 83
The Role of High-Density Lipoproteins in Diabetes and Its Vascular Complications
Wong, N. K. P., Nicholls, S. J., Tan, J. T. M., & Bursill, C. A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061680 · Cited by 77
Gourgari, E., Ma, J., Playford, M. P., Mehta, N. N., Goldman, R., Remaley, A. T., & Gordon, S. M. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0846-9 · Cited by 76
Modified Lipoproteins Induce Arterial Wall Inflammation During Atherogenesis
Lorey, M. B., Öörni, K., & Kovanen, P. T. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.841545 · Cited by 82
Pharmacological Intervention to Modulate HDL: What Do We Target?
Woudberg, N. J., Pedretti, S., Lecour, S., Schulz, R., Vuilleumier, N., James, R. W., & Frias, M. A. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00989 · Cited by 80
Cholesterol efflux capacity: An introduction for clinicians
Anastasius, M. O., Kockx, M., Jessup, W., SULLIVAN, D. R., Rye, K., & Kritharides, L. (2016) · American Heart Journal · doi:10.1016/j.ahj.2016.07.005 · Cited by 78
Khoudary, S. R. E., Chen, X., Nasr, A., Billheimer, J. T., Brooks, M. M., McConnell, D. S., Orchard, T. J., Crawford, S. L., Matthews, K. A., & Rader, D. J. (2020) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.120.315355 · Cited by 83
Soria-Florido, M. T., Castañer, O., Lassale, C. M., Estruch, R., Salas‐Salvadó, J., Martínez‐González, M. Á., Corella, D., Ros, E., Arós, F., Elosúa, R., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.041658 · Cited by 79
Ollikainen, E., Tulamo, R. M., Lehti, S., Lee‐Rueckert, M., Hernesniemi, J. A., Niemela, M. R., Ylä‐Herttuala, S., Kovanen, P. T., & Frösén, J. (2016) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlw041 · Cited by 75
Association Between Oxidation-Modified Lipoproteins and Coronary Plaque in Psoriasis
Sorokin, A. V., Kotani, K., Elnabawi, Y. A., Dey, A. K., Sajja, A. P., Yamada, S., Ueda, M., Harrington, C. L., Baumer, Y., Rodante, J. A., et al. (2018) · Circulation Research · doi:10.1161/circresaha.118.313608 · Cited by 73
Secondary dyslipidemia: its treatments and association with atherosclerosis
Yanai, H., & Yoshida, H. (2020) · Global Health & Medicine · doi:10.35772/ghm.2020.01078 · Cited by 71
Oxidative Stress in Human Atherothrombosis: Sources, Markers and Therapeutic Targets
Martín-Ventura, J. L., Rodrigues‐Díez, R., Martínez-López, D., Salaíces, M., Blanco‐Colio, L. M., & Briones, A. M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112315 · Cited by 71
Vaisar, T., Kanter, J. E., Wimberger, J., Irwin, A. D., Gauthier, J., Wolfson, E. A., Bahnam, V., Wu, I., Shah, H., Keenan, H. A., et al. (2019) · Diabetes Care · doi:10.2337/dc19-0772 · Cited by 69
Self-citationGordon, S. M., & Remaley, A. T. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.11.015 · Cited by 72
Rethinking good cholesterol: a clinicians' guide to understanding HDL
Xiang, A. S., & Kingwell, B. A. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30003-8 · Cited by 70
Genotype-Dependent Effects of Dalcetrapib on Cholesterol Efflux and Inflammation
Tardif, J., Rhainds, D., Brodeur, M. R., Zada, Y. F., Fouodjio, R., Provost, S., Boulé, M., Alem, S., Grégoire, J. C., L’Allier, P. L., et al. (2016) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.116.001405 · Cited by 69
Gille, A., D’Andrea, D. M., Tortorici, M. A., Härtel, G., & Wright, S. D. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.310538 · Cited by 69
Damen, M. S. M. A., Popa, C. D., Netea, M. G., Dinarello, C. A., & Joosten, L. A. B. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.07.005 · Cited by 68
HDL cholesterol and ASCVD risk stratification: A debate
Barter, P. J., & Genest, J. J. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.01.001 · Cited by 68
Self-citationMaki, K. C., Guyton, J. R., Orringer, C. E., Hamilton-Craig, I., Alexander, D. D., & Davidson, M. H. (2016) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2016.03.008 · Cited by 62
Yang, S., Ye, Z.-M., Chen, S., Luo, X., Chen, S., Mao, L., Li, Y., Jin, H., Cheng, Y., Xiang, F., et al. (2018) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2018.09.004 · Cited by 68
Li, X., Li, Q., Ju, L., Zhao, C. N., Zhao, L., Du, J., Wang, Y., Zheng, L., Song, B., Li, L., et al. (2020) · Hepatology · doi:10.1002/hep.31594 · Cited by 62
Emerging insights into the relationship between hyperlipidemia and the risk of diabetic retinopathy
Chou, Y., Ma, J., Su, X., & Zhong, Y. (2020) · Lipids in Health and Disease · doi:10.1186/s12944-020-01415-3 · Cited by 63
Toma, L., Stancu, C. S., & Sima, A. V. (2020) · Biomedicines · doi:10.3390/biomedicines9010018 · Cited by 66
HDL Dysfunctionality: Clinical Relevance of Quality Rather Than Quantity
Bonizzi, A., Piuri, G., Corsi, F., Cazzola, R., & Mazzucchelli, S. (2021) · Biomedicines · doi:10.3390/biomedicines9070729 · Cited by 71
Frej, C., Mendez, A. J., Ruiz, M., Castillo, M., Hughes, T. A., Dahlbäck, B., & Goldberg, R. B. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.309275 · Cited by 62
HDL: Fact, fiction, or function? HDL cholesterol and cardiovascular risk
Allard‐Ratick, M., Kindya, B., Khambhati, J., Engels, M. C., Sandesara, P. B., Rosenson, R. S., & Sperling, L. S. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319848214 · Cited by 66
Self-citationLipid metabolism in women: A review
van Oortmerssen, J. A. E., Mulder, J. W. C. M., Kavousi, M., & van Lennep, J. E. R. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.119213 · Cited by 61
New Era of Lipid-Lowering Drugs
Barter, P. J., & Rye, K. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.012203 · Cited by 59
Self-citationOtvos, J. D., Guyton, J. R., Connelly, M. A., Akapame, S., Bittner, V., Kopecky, S. L., Lacy, M., Marcovina, S. M., Muhlestein, J. B., & Boden, W. E. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.01.002 · Cited by 58
Zhai, L., Ning, Z., Huang, T., Wen, B., Liao, C., Lin, C., Zhao, L., Xiao, H., & Bian, Z. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00973 · Cited by 58
Wang, H., Shi, W., Yi, X., Zhou, Y., Wang, Z., & Sun, Y. (2019) · Lipids in Health and Disease · doi:10.1186/s12944-019-1076-6 · Cited by 58
HDL Proteome and Alzheimer’s Disease: Evidence of a Link
Marsillach, J., Adorni, M. P., Zimetti, F., Papotti, B., Zuliani, G., & Cervellati, C. (2020) · Antioxidants · doi:10.3390/antiox9121224 · Cited by 62
Deepening our understanding of HDL proteome
Ronsein, G. E., & Vaisar, T. (2019) · Expert Review of Proteomics · doi:10.1080/14789450.2019.1650645 · Cited by 57
High density lipoprotein mimicking nanoparticles for atherosclerosis
Chen, J., Zhang, X., Millican, R. C., Creutzmann, J. E., Martin, S., & Jun, H. (2020) · Nano Convergence · doi:10.1186/s40580-019-0214-1 · Cited by 57
Zhang, X., Zhu, Y., Song, F., Yao, Y., Ya, F., Li, D., Ling, W., & Yang, Y. (2016) · Nutrition & Metabolism · doi:10.1186/s12986-016-0146-2 · Cited by 56
microRNAs in lipoprotein and lipid metabolism: from biological function to clinical application
Desgagné, V., Bouchard, L., & Guérin, R. (2016) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2016-0575 · Cited by 57
Li, L., Xu, L., Chen, W., Li, X., Xia, Q., Zheng, L., Duan, Q., Zhang, H., & Zhao, Y. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00347 · Cited by 56
In search of biomarkers for leprosy by unraveling the host immune response to Mycobacterium leprae
van Hooij, A., & Geluk, A. (2021) · Immunological Reviews · doi:10.1111/imr.12966 · Cited by 55
Qi, X., Hou, R., Xie, L., Niu, M., Pan, X., & Zhu, X. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1257 · Cited by 55
Kullisaar, T., Zilmer, K., Salum, T., Rehema, A., & Zilmer, M. (2016) · Nutrition Journal · doi:10.1186/s12937-016-0213-6 · Cited by 55
Structures of Angptl3 and Angptl4, modulators of triglyceride levels and coronary artery disease
Biterova, E., Esmaeeli, M., Alanen, H. I., Saaranen, M., & Ruddock, L. W. (2018) · Scientific Reports · doi:10.1038/s41598-018-25237-7 · Cited by 53
High-Density Lipoprotein Carries Markers That Track With Recovery From Stroke
Plubell, D. L., Fenton, A. M., Rosário, S., Bergstrom, P., Wilmarth, P. A., Clark, W. M., Zakai, N. A., Quinn, J. F., Minnier, J., Alkayed, N. J., et al. (2020) · Circulation Research · doi:10.1161/circresaha.120.316526 · Cited by 56
Nandwana, V., Ryoo, S., Kanthala, S., McMahon, K. M., Rink, J. S., Li, Y., Venkatraman, S. S., Thaxton, C. S., & Dravid, V. P. (2017) · Chemistry of Materials · doi:10.1021/acs.chemmater.6b05357 · Cited by 55
Dual-Targeted Synthetic Nanoparticles for Cardiovascular Diseases
Banik, B., Surnar, B., Askins, B. W., Banerjee, M., & Dhar, S. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b19036 · Cited by 54
Myeloperoxidase: a potential therapeutic target for coronary artery disease
Chaikijurajai, T., & Tang, W. H. W. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1762177 · Cited by 53
LCAT- targeted therapies: Progress, failures and future
Yang, K., Wang, J., Xiang, H., Ding, P., Wu, T., & Ji, G. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112677 · Cited by 55
Metadata
- Authors
- Rosenson, R. S., Brewer, H. B., Ansell, B. J., Barter, P., Chapman, M. J., Heinecke, J. W., Kontush, A., Tall, A. R., & Webb, N. R.
- Affiliations
- Icahn School of Medicine at Mount Sinai (US)
- MedStar Washington Hospital Center (US)
- University of California, Los Angeles (US)
- UNSW Sydney (AU)
- Inserm (FR)
- University of Washington (US)
- Columbia University (US)
- University of Kentucky (US)
- Corresponding author
- Rosenson, Robert S.
- Venue
- Nature Reviews Cardiology
- Published
- 2015-09-01
- Volume
- 13
- Issue
- 1
- Pages
- 48-60
- ISSN
- 1759-5002 (ISSN-L)
- 1759-5010
- PMC
- PMC6245940
- OpenAlex
- W2175680864
- Cited by
- 822
- References
- 131
- Citations by year
- 2026: 89 · 2025: 89 · 2024: 66 · 2023: 79 · 2022: 86 · 2021: 79 · 2020: 79 · 2019: 62 · 2018: 69 · 2017: 61 · 2016: 56 · 2015: 5
- FWCI
- 12.01
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Cardiology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (DP3DK108209, P30DK017047)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- HDL dysfunction, atherosclerosis, apolipoprotein A-I, reverse cholesterol transport, ABCA1, ABCG1, myeloperoxidase, nitrosylation, oxidative modification, inflammation, endothelial function, coronary artery disease, atherogenesis, anti-inflammatory activity
- MeSH terms
- Humans, Lipoproteins, HDL, Macrophages, Smoking, Apolipoprotein A-I, ATP-Binding Cassette Transporters, Diabetes Complications, Atherosclerosis, ATP Binding Cassette Transporter 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
